Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis

Clinical Therapeutics

Volumn 24, Issue 6, 2002, Pages 906-917

  Anzueto, Antonio ^a   Gotfried, Mark ^a   Wikler, Matthew A ^a   Russo, Rene ^a   Nicholson, Susan C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Fluoroquinolone; Gatifloxacin

Indexed keywords

ANTIINFECTIVE AGENT; GATIFLOXACIN; QUINOLONE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; POSTMARKETING SURVEILLANCE; RISK FACTOR; SMOKING; SPUTUM; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL EXAMINATION; CLINICAL TRIAL; COMMUNITY MEDICINE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GRAM STAINING; HAEMOPHILUS INFLUENZAE; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MICROSCOPE; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; PENICILLIN RESISTANCE; RESPIRATORY TRACT INFECTION; SPUTUM EXAMINATION; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; TELEPHONE; VERTIGO; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BRONCHITIS, CHRONIC; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; SPUTUM;

EID: 0035986659     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80006-6     Document Type: Article

References (34)

1. The role of antimicrobial therapy in acute exacerbations of chronic bronchitis
2. Infectious etiology of acute exacerbations of chronic bronchitis
3. Infection in acute exacerbations of chronic bronchitis: A clinical perspective
4. Chronic bronchitis and acute infectious exacerbations
5. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections
6. Antibiotic therapy of exacerbations of chronic bronchitis
7. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
8. Acute exacerbation of COPD: Factors associated with poor treatment outcome
9. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance?
10. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: The tip of the iceberg?
11. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia
12. New antibiotics in pulmonary and critical care medicine: Focus on advanced generation quinolones and cephalosporins
13. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones.'
14. Relationship of underlying bronchitis risk factors to susceptibility of respiratory pathogens in patients with AECB
15. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: Microbiology from the medical office practice environment
16. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
17. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance
18. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
19. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants
20. Mechanism of action and resistance of older and newer fluoroquinolones
21. In vitro activity of newer fluoroquinolones for respiratory tract infection and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program
22. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone
23. Clinical pharmacology of gatifloxacin, a new fluoroquinolone
24. A novel approach to postmarketing surveillance: The Tequin Clinical Experience study
25. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
26. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
27. Comparison of 5-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbations of chronic bronchitis
28. Diagnosis and treatment of upper respiratory tract infections in the primary care setting
29. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
30. Expanded activity and utility of the new fluoroquinolones: A review
31. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae